Lorundrostat is an oral aldosterone synthase inhibitor targeting the treatment of hypertension, obstructive sleep apnoea, and ...

Mineralys Therapeutics (MLYS) announced detailed results from the pivotal Phase 3 Launch-HTN trial in over 1,000 participants ...

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension ...

Mineralys expects to announce top-line data from the Explore-CKD trial later in the current quarter. The Chief Executive Officer confirmed the company's intention to submit an NDA for lorundrostat ...

The last time I wrote about Mineralys Therapeutics (NASDAQ:MLYS) it was with respect to a Seeking Alpha article entitled "Mineralys: 2nd Half 2024 Hypertension Data Readout". In this article ...

Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.

Abnormal aldosterone production is considered a key driver in uncontrolled and resistant hypertension,” stated Jon Congleton, Chief Executive Officer of Mineralys. “Lorundrostat has already ...

Mineralys Therapeutics is working on a treatment for patients with uncontrolled hypertension. New York veterinary operator opens Main Line clinic © 2025 American ...

March 10 (Reuters) - Mineralys Therapeutics (MLYS.O), opens new tab said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and ...